key: cord-0913088-v96yr2vf
authors: Kharbanda, Rajat; Ganatra, Keya; Abbasi, Maryam; Agarwal, Vikas; Gupta, Latika
title: Patients with idiopathic inflammatory myopathies suffer from worse self-reported PROMIS physical function after COVID-19 infection: an interview-based study from the MyoCite cohort
date: 2022-05-14
journal: Clin Rheumatol
DOI: 10.1007/s10067-022-06204-0
sha: d7453ce80d3aebc62e1e053302a0aeed22976353
doc_id: 913088
cord_uid: v96yr2vf

nan

the infection, and vaccination status. Baseline characteristics were retrieved from the MyoCite registry and biobank archive [2] . PROMIS-10a, a validated self-report tool [3, 4] , was used to quantify physical function [5] . Age and gender similar healthy controls (HC) were included for comparison.

Ten patients of IIM were compared with 40 controls. Fever was the most common symptom during COVID infection reported by both the groups. IIM patients were more likely to experience fatigue, chest pain, and breathlessness as compared to HC. Notably, the severity of COVID-19 infection as substantiated by pneumonia, hospitalization, and oxygen requirement was comparable in both groups in this small study population. IIM patients were also more likely to experience shortness of breath (40% v 0%), rashes (20% v 0%), and muscle weakness (30% v 0%) 30 days post-COVID than HC. Notably, 3 of 4 individuals who experienced breathlessness had ILD, suggesting the need for closer follow-up in this group.

PROMIS physical function was comparable pre-COVID in both groups. After recovery from COVID infection, 30-day PROMIS physical function scores were suggestive of weaker performance in the IIM group in specific tasks such as climbing stairs, walking more than a mile, bending, kneeling, or stooping suggesting significant decline in lower limb function. Upper limb tasks such as shampooing hair were impacted as well, albeit with mild difference (Table 1) . Notably, the aggregate PROMIS physical function was comparable, suggesting overall favorable outcomes with respect to long COVID in IIM patients ( Table 2) .

It is noteworthy that IIM patients were less likely to be vaccinated, suggesting prevalent hesitancy in this group (50% vs 90%, p: 0.007). (Supplementary Table S1 ).

To conclude, IIM patients, especially those with underlying ILD, may be particularly predisposed to symptomatic COVID infection and dyspnoea on exertion 30 days post-COVID (Table 2) . Short-term physical function is impacted at 30 days post-COVID-19, suggesting the need for closer long-term follow-up and systematically analyze 60-and 90-day outcomes. We hope that future studies in a larger study population allowing analysis of stratified subsets of disease activity would provide further understanding of long COVID in myositis patients. Difficulty in performing specific tasks post-COVID may warrant focused therapies for the specific muscle groups involved.

Vaccine hesitancy is prevalent among Indian patients with IIM, and may benefit from focused group education initiatives [6, 7] . (Supplementary Table S2 ).

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10067-022-06204-0.

Author contribution All authors reviewed the study design and contributed to data interpretation and critical revision of the article. All authors approved the version of the article to be published. 

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Development of the MyoCite biobank: cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis

Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis

Utility of patientreported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy

Responsiveness of patient-reported outcomes measurement information system measures in rheumatoid arthritis patients starting or switching a disease-modifying antirheumatic drug

COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study